Search by Algolia
Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Lionheart HoldingsLionheart Holdings Reports $2.25 Million Net Income for Quarter Ending June 30, 2025
MIDDLEFIELD BANC CORPMiddlefield Banc Corp. Reports 47.9% Increase in Q2 Net Income to $6.2 Million
CHAIN BRIDGE BANCORP INCChain Bridge Bancorp Reports $10.2 Million Net Income for First Half of 2025
Autolus Therapeutics plcAutolus Therapeutics Reports $20.9M Product Revenue in Q2 2025, Net Loss of $47.9M
Rigetti Computing, Inc.Rigetti Computing Reports 42% Revenue Decline in Q2 2025, Net Loss of $39.7 Million
Kyverna Therapeutics, Inc.Kyverna Therapeutics Reports $42.1 Million Net Loss in Q2 2025, Increases Investment in Clinical Trials
ADC Therapeutics SAADC Therapeutics Reports 8.2% Revenue Growth but Increases Net Loss in Q2 2025
Prairie Operating Co.Prairie Operating Co. Reports $68.1 Million Revenue and $35.7 Million Net Income for Quarter Ending June 30, 2025
TriSalus Life Sciences, Inc.TriSalus Life Sciences Reports 52.3% Revenue Growth but Incurred $9M Net Loss in Q2 2025
Slide Insurance Holdings, Inc.Slide Insurance Holdings Reports 25.1% Revenue Growth to $261.6 Million in Q2 2025
SKYX Platforms Corp.SKYX Platforms Reports 8% Revenue Growth to $23.1 Million in Q2 2025
EXOZYMES INC.eXoZymes Reports $4.22 Million Net Loss and Significant Financial Challenges
PARKERVISION INCParkerVision Reports $5.4 Million Net Loss and Increased Operating Expenses for First Half of 2025
FATE THERAPEUTICS INCFate Therapeutics Reports Decrease in Collaboration Revenue and Net Loss for Q2 2025
374Water Inc.374Water Inc. Reports 223% Revenue Increase but Faces Significant Net Loss in Q2 2025
vTv Therapeutics Inc.vTv Therapeutics Reports $6M Net Loss and Zero Revenue for Q2 2025
Metagenomi Therapeutics, Inc.Metagenomi Reports Significant Revenue Decline and Increased Net Loss in Q2 2025
Caribou Biosciences, Inc.Caribou Biosciences Reports $54.1 Million Net Loss in Q2 2025
Editas Medicine, Inc.Editas Medicine Reports Q2 2025 Financial Results with Reduced Net Loss and Increased R&D Revenues
Maze Therapeutics, Inc.Maze Therapeutics Reports No Revenue and $33.7 Million Net Loss for Q2 2025
ALX ONCOLOGY HOLDINGS INCALX Oncology Reports $25.9 Million Net Loss in Q2 2025, Focuses on Clinical Pipeline
ANAVEX LIFE SCIENCES CORP.Anavex Life Sciences Reports $13.2 Million Net Loss in Q3 Fiscal 2025
IZEA Worldwide, Inc.IZEA Worldwide Reports $1.2 Million Net Income in Q2 2025, Revenue Slightly Up
GLADSTONE INVESTMENT CORPORATION\DEGladstone Investment Corporation Reports Q2 2025 Financial Results with Increased Investment Income
Anterix Inc.Anterix Inc. Reports $25.2 Million Net Income Turnaround for Q2 2025